Orchestra BioMed Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $33.5M | $2.6M | $2.8M | $3.5M | — |
| Cost of revenue | $190,000 | $204,000 | $186,000 | $211,000 | — |
| Selling, general & administrative | $26.9M | $23.9M | $20.3M | $14.0M | — |
| Research and development | $58.2M | $42.8M | $33.8M | $21.9M | — |
| Operating income | -$51.8M | -$64.3M | -$51.5M | -$32.7M | -$394,756 |
| Income tax expense | $0 | — | — | — | — |
| Net income | -$52.7M | -$61.0M | -$49.1M | -$33.6M | -$378,753 |
| Balance Sheet | |||||
| Cash and equivalents | $34.7M | $22.3M | $30.6M | $19.8M | $1.8M |
| Current assets | $107.9M | $69.2M | $89.1M | $84.7M | $1.8M |
| Total assets | $114.9M | $76.2M | $95.2M | $95.6M | $161.8M |
| Current liabilities | $16.7M | $16.2M | $11.2M | $18.6M | $165,539 |
| Total liabilities | $51.5M | $43.2M | $27.2M | $43.0M | $5.8M |
| Stockholders' equity | $53.6M | $33.0M | $68.0M | -$6.9M | -$3.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$49.0M | -$50.6M | -$46.1M | -$29.3M | -$272,362 |
| Depreciation and amortization | $327,000 | $308,000 | $287,000 | $222,000 | — |
| Stock-based compensation | $12.0M | $10.6M | $7.6M | $3.4M | — |
| Capital expenditure | $489,000 | $289,000 | $78,000 | $591,000 | — |
| Free cash flow | -$49.5M | -$50.8M | -$46.2M | -$29.9M | — |
| Dividends paid | — | — | — | $20.0M | — |
| Impairments | $0 | $0 | $0 | $5.0M | $5.0M |
Shares outstanding 59.9M · Free float 38.2%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.